ArticleCancer medicine2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.BMC cancer · 2023Pooled it
- Atezolizumab-bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3.JHEP reports : innovation in hepatology · 2026Observational
- Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.Cancer medicine · 2025Article
- Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2025Article
- Management of hepatocellular carcinoma in elderly and adolescent/young adult populations.Journal of liver cancer · 2025Article
- Immunotherapy combined with targeted therapy and transcatheter arterial chemoembolization: a promising approach for advanced liver cancer.American journal of translational research · 2025Article
- Observational
- The current status and future of targeted-immune combination for hepatocellular carcinoma.Frontiers in immunology · 2024Review
- The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.Frontiers in immunology · 2024Article
- Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.Targeted oncology · 2024Article
- Chronic Liver Disease in the Older Patient-Evaluation and Management.Current gastroenterology reports · 2023Review
- Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence.International cancer conference journal · 2023Article
- Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report.World journal of gastrointestinal oncology · 2023Article
- Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.Investigational new drugs · 2023Article
- Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.Cancer medicine · 2023Article
- FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?International journal of molecular sciences · 2023Review
- The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea.Clinical and molecular hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe safety and efficacy of atezolizumab plus bevacizumab (Atez/Bev) in elderly patients with unresectable hepatocellular carcinoma (HCC) have not been sufficiently investigated.
methodsA total of 317 patients with HCC treated with Atez/Bev were studied. We compared the survival and frequency of adverse events in elderly versus non-elderly patients with HCC who were treated with Atez/Bev using an analysis of inverse probability weighting (IPW).
resultsUnivariate analysis adjusted with IPW showed that being elderly is not associated with worse overall or progression-free survival (hazard ratio [HR], 1.239; 95% confidence interval [CI], 0.640-2.399; p = 0.526 and HR, 1.256; 95% CI, 0.871-1.811; p = 0.223, respectively). Regarding treatment-related adverse events, any grade of fatigue, proteinuria, decreased appetite, hypertension, and liver injury occurred in ≥10% of patients. There were no significant differences in treatment-related adverse events between the elderly and non-elderly groups. In a subgroup analysis of elderly patients aged 75-79, 80-84, or ≥ 85 years, there were no significant differences in cumulative overall or progression-free survival among these age groups (p = 0.960 and 0.566, respectively). In addition, there were no significant differences in treatment-related adverse events among these three age groups, except for proteinuria of any grade. In a subgroup analysis of patients treated with Atez/Bev as first-line systemic therapy, there were no significant differences in cumulative overall or progression-free survival between the elderly and non-elderly groups (p = 0.728 and 0.805, respectively).
conclusionsAtez/Bev can be used efficaciously and safely in spite of age in patients with unresectable HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.